Clinical Trials Logo

Filter by:
NCT ID: NCT05715632 Recruiting - Gastric Cancer Clinical Trials

New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of carelizumab combined with XELOX regimen in neoadjuvant treatment of locally advanced resectable gastric cancer

NCT ID: NCT05715606 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Start date: February 10, 2023
Phase: Early Phase 1
Study type: Interventional

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05715424 Recruiting - Myopia Clinical Trials

Community Intervention and Demonstration Area Construction

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The objective of this intervention study was to understand the visual health status of nearly one million children and adolescents in ten provinces in China, and then to conduct intervention and evaluate the effect of intervention measures with the development of myopia as the outcome indicator. The study will be conducted in the form of a stepped intervention and will answer the following questions. Current China children and adolescent's vision health, including the different degrees of myopia prevalence, and farsightedness reserve status. To evaluate the implementation and effect of eight appropriate technologies and six interventions developed in this study, to reduce the incidence of myopia among children and adolescents in China, to achieve the purpose of nationwide application. In the early stage of this study, a baseline survey will be conducted on participants. In the middle stage, participants will be required to adjust the seat height regularly and increase the time for outdoor activities, etc. In the later stage, intervention measures will be evaluated based on the overall research situation to consider national promotion.

NCT ID: NCT05715333 Recruiting - Healthy Clinical Trials

Study of CM326 Injection in Healthy Subjects

Start date: March 21, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, randomized, double-blind, placebo-controlled, dose-increasing phase I clinical study.

NCT ID: NCT05715320 Recruiting - Atopic Dermatitis Clinical Trials

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Start date: March 10, 2023
Phase: Phase 2
Study type: Interventional

This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.

NCT ID: NCT05715307 Recruiting - Type 2 Diabetes Clinical Trials

Chinese Endocrinologists Health Education Study

CREATION
Start date: February 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to conduct a prospective, multicenter, cluster randomized control study, evaluating the improvement for T2DM diagnosis and treatment ability in Chinese endocrinologists after 1-week intensive experiential diabetes management training in the leading center.

NCT ID: NCT05714904 Recruiting - Clinical trials for Bietti's Crystalline Dystrophy

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Start date: September 23, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of an adeno-associated virus vector expressing CYP4V2 in patients with Bietti's crystalline dystrophy (BCD).

NCT ID: NCT05714748 Recruiting - Malignant Tumors Clinical Trials

Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

Start date: November 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for the EBV-positive Advanced Malignant Tumors.

NCT ID: NCT05714566 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients

Start date: November 7, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this research is to compare alterations of gut microbiota and fecal metabolomics alterations between inflammatory bowel disease patients infected with or without Clostridioides difficile. The main questions it aim to answer are: which bacterial genus or fecal metabolites can discriminate IBD patients infected or more likely to be infected with Clostridioides difficile and their role in the pathogenesis of Clostridioides difficile. type of study: observational study participant population/health conditions 1. population diagnosed with Ulcerative colitis or Crohn's disease 2. Having diarrhea Participants will be included in this research. If there is a comparison group: Researchers will compare healthy people without IBD or any diarrhea to see if disease or diarrhea would affect the gut microbiota and metabolites.

NCT ID: NCT05714202 Recruiting - Bladder Cancer Clinical Trials

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

SunRISe-3
Start date: March 23, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).